Inflammatory stress increases hepatic CD36 translational efficiency via activation of the mTOR signalling pathway

PLoS One. 2014 Jul 21;9(7):e103071. doi: 10.1371/journal.pone.0103071. eCollection 2014.

Abstract

Inflammatory stress is an independent risk factor for the development of non-alcoholic fatty liver disease (NAFLD). Although CD36 is known to facilitate long-chain fatty acid uptake and contributes to NAFLD progression, the mechanisms that link inflammatory stress to hepatic CD36 expression and steatosis remain unclear. As the mammalian target of rapamycin (mTOR) signalling pathway is involved in CD36 translational activation, this study was undertaken to investigate whether inflammatory stress enhances hepatic CD36 expression via mTOR signalling pathway and the underlying mechanisms. To induce inflammatory stress, we used tumour necrosis factor alpha (TNF-α) and interleukin-6 (IL-6) stimulation of the human hepatoblastoma HepG2 cells in vitro and casein injection in C57BL/6J mice in vivo. The data showed that inflammatory stress increased hepatic CD36 protein levels but had no effect on mRNA expression. A protein degradation assay revealed that CD36 protein stability was not different between HepG2 cells treated with or without TNF-α or IL-6. A polysomal analysis indicated that CD36 translational efficiency was significantly increased by inflammatory stress. Additionally, inflammatory stress enhanced the phosphorylation of mTOR and its downstream translational regulators including p70S6K, 4E-BP1 and eIF4E. Rapamycin, an mTOR-specific inhibitor, reduced the phosphorylation of mTOR signalling pathway and decreased the CD36 translational efficiency and protein level even under inflammatory stress resulting in the alleviation of inflammatory stress-induced hepatic lipid accumulation. This study demonstrates that the activation of the mTOR signalling pathway increases hepatic CD36 translational efficiency, resulting in increased CD36 protein expression under inflammatory stress.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Hep G2 Cells
  • Humans
  • Inflammation / metabolism*
  • Interleukin-6 / pharmacology
  • Liver / drug effects
  • Liver / metabolism*
  • Male
  • Mice
  • Non-alcoholic Fatty Liver Disease / metabolism
  • Phosphorylation
  • Protein Biosynthesis*
  • Receptors, Complement 3b / metabolism*
  • Signal Transduction / drug effects
  • Signal Transduction / physiology*
  • TOR Serine-Threonine Kinases / metabolism*
  • Tumor Necrosis Factor-alpha / pharmacology

Substances

  • Interleukin-6
  • Receptors, Complement 3b
  • Tumor Necrosis Factor-alpha
  • TOR Serine-Threonine Kinases

Grants and funding

This study was supported by the National Natural Science Foundation of China (81270493, 81200567, 81270789 and Key Program, no. 81030008, 81390354), National Basic Research Program of China (973 Program, NO. 2012CB517700 & 2012CB517500). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.